Home > Media Centre
Media Centre
Press releases
400 PATIENTS HAVE BEEN ENROLLED IN AM-PHARMA’s PIVOTAL PHASE 3 STUDY OF ILOFOTASE ALFA FOR THE TREATMENT OF SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY
Decision from the first pre-specified futility analysis at…
AM-Pharma to Participate in SVB Leerink Biopharma Private Company Connect
Utrecht, The Netherlands, March 22, 2022 – AM-Pharma B.V.,…
AM-PHARMA ANNOUNCES TWO PRESENTATIONS AT THE 27TH INTERNATIONAL CONFERENCE ON ADVANCES IN CRITICAL CARE NEPHROLOGY
The lead investigator will present an overview of AM-Pharma’s…
AM-Pharma to Participate in Upcoming Investor and Scientific Conferences
UTRECHT, The Netherlands - AM-Pharma B.V., an emerging leader…
AM-Pharma and Leading Experts Publish Report on State-of-the-Art Clinical Trials in Acute Kidney Injury
Utrecht, The Netherlands, January 26, 2022 – AM Pharma B.V.,…
Publications
Human recombinant alkaline phosphatase inhibits ex vivo platelet activation in humans
View publication
Biodistribution and translational pharmacokinetic modeling of a human recombinant alkaline phosphatase
View publication
Alkaline phosphatase protects against renal inflammation through dephosphorylation of lipopolysaccharide and adenosine triphosphate
View publication
Catalytic Signature of a Heat-Stable, Chimeric Human Alkaline Phosphatase with Therapeutic Potential
View publication